XC101 / Xoc Pharma - LARVOL DELTA

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=32; Active, not recruiting; Sponsor: Xoc Pharmaceuticals; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2020 ➔ Mar 2022; Trial primary completion date: Dec 2019 ➔ Jan 2022

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Migraine

[VIRTUAL] Development of a Novel, Clinical-stage Drug for the Prevention of Migraine Based on Receptor Activity Mapping and Achievement of a Target Receptor Profile (AAN 2021) - "Xoc developed a novel clinical stage compound, XC101-D13H, with the desired target receptor profile for safe and effective migraine preventive therapy. XC101-D13H entered human clinical trials in 2019."

Clinical • CNS Disorders • Migraine

[VIRTUAL] Interim Results of a Phase 1 Single Ascending Dose Study of XC101-D13H, a Novel Compound for the Prevention of Migraine (AHS 2020) - "In the early cohorts of this Phase 1 study, XC130-D13H was well tolerated and showed suitable pharmacokinetics for daily oral dosing. The receptor profile and initial clinical results support the prospect that XC101-D13H can prevent migraine without inducing the most important serotonergic agonist-driven side effects."

P1 data • CNS Disorders • Migraine • Pain

Development of a Novel Drug for the Prevention of Migraine based on Receptor Activity Mapping and Achievement of a Target Receptor Profile (AAN 2020) - "Xoc developed a target receptor profile for effective migraine preventive therapeutics and a novel clinical stage compound, XC101-D13H. XC101-D13H entered human clinical trials in 2019."